Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.

Molecular cancer therapeutics·2026
Same author

Rat somatic genome editing enables ER+ breast cancer modeling.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis.

Circulation research·2026
Same author

Asbestos exposure induces malignant-like phenotypes via minority MOMP and displays characteristics of drug-tolerant persister cells.

Carcinogenesis·2026
Same author

Hyaluronidase-1 mediates postprandial suppression of hepatic gluconeogenesis.

Life metabolism·2026
Same author

Epigenetic Programming of Macrophage Phenotypes by STING-IRF3 Drives Inflammation in Ascending Thoracic Aortic Dissection.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Sep 9, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K

Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma.

Yuan Xu1, Cristian G Medina1, Deborah R Surman2

  • 1David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery and the Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Molecular Cancer Therapeutics
|September 4, 2025
PubMed
Summary

Targeting MCL-1, not co-targeting BCL-xL and MCL-1, enhances chemotherapy efficacy in diffuse mesothelioma. This approach lowers the apoptosis threshold and improves chemosensitivity without toxicity in models.

More Related Videos

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro
13:20

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro

Published on: July 17, 2018

10.5K
Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.0K

Related Experiment Videos

Last Updated: Sep 9, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K
Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro
13:20

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro

Published on: July 17, 2018

10.5K
Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Diffuse mesothelioma is an aggressive cancer with limited treatment options and high resistance.
  • Anti-apoptotic proteins MCL-1 and BCL-xL contribute to therapeutic resistance by inhibiting apoptosis.
  • Understanding resistance mechanisms is crucial for developing effective mesothelioma treatments.

Purpose of the Study:

  • To investigate the consistency of B-cell homology domain3 profiles across different mesothelioma models.
  • To evaluate the efficacy of co-targeting MCL-1 and BCL-xL in diffuse mesothelioma.
  • To identify safe and effective therapeutic strategies for diffuse mesothelioma.

Main Methods:

  • B-cell homology domain3 profiling was used to compare tumor samples, patient-derived cells, and xenografts.
  • In vitro studies assessed the effects of co-targeting BCL-xL and MCL-1 on cell viability and apoptosis.
  • In vivo studies in patient-derived xenografts (PDX) evaluated the therapeutic potential of targeting these proteins.

Main Results:

  • B-cell homology domain3 profiles were consistent across intra-patient models, enabling cross-model comparisons.
  • Co-targeting BCL-xL and MCL-1 showed synergistic effects on reducing cell viability and increasing apoptosis in vitro.
  • In vivo co-targeting led to synthetic lethality in PDX models, indicating a lack of safety for clinical development.
  • Targeting MCL-1 alone decreased the apoptosis threshold, enhanced chemosensitivity, and showed no toxicity in PDX models.

Conclusions:

  • Targeting MCL-1 alone is a potentially safe strategy to enhance chemotherapy efficacy in diffuse mesothelioma.
  • Co-targeting BCL-xL and MCL-1 is not a safe clinical approach due to synthetic lethality.
  • Future clinical strategies should focus on MCL-1 inhibition to overcome therapeutic resistance in mesothelioma.